Market Overview 2025-2033

The Europe medical cannabis market size reached USD 2,586.1 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 12,652.9 Million by 2033, exhibiting a growth rate (CAGR) of 18.33% during 2025-2033. The market is growing due to increasing legalization, rising medical applications, and expanding research initiatives. Innovations in product development, regulatory support, and patient demand are driving expansion, making it a dynamic and evolving industry.

Key Market Highlights:

✔️ Rapid market growth driven by increasing legalization and acceptance of cannabis for medical use

✔️ Rising demand for cannabis-based treatments in pain management, neurology, and oncology

✔️ Expanding research and investment in pharmaceutical-grade cannabis production and innovation

Request for a sample copy of the report: https://www.imarcgroup.com/europe-medical-cannabis-market/requestsample

Europe Medical Cannabis Market Trends and Drivers:

The Europe medical cannabis industry is experiencing rapid expansion as more countries recognize the therapeutic potential of cannabis for conditions such as chronic pain, anxiety, and neurological disorders. Germany, the UK, and Portugal are leading this shift by easing patient access to cannabis-based treatments. Notably, Germany’s decision in early 2024 to broaden its medical cannabis program to cover more conditions resulted in a 40% surge in prescriptions, highlighting the increasing European medical cannabis market size.

Support from regulatory bodies like the European Medicines Agency (EMA) is also accelerating the industry. By streamlining the approval process for cannabis-based therapies, the EMA has boosted confidence among healthcare professionals and patients alike. However, the lack of harmonized regulations across the EU remains a challenge. France and Italy still require individualized approvals, while Sweden continues to exercise caution. These disparities underscore the need for a unified regulatory framework to support Europe medical cannabis market growth.

Quality control is critical in cannabis cultivation, and countries like Spain and the Netherlands are setting high standards for safety and consistency. As a result, investor confidence is climbing. In 2024, investment in the Europe medical cannabis industry rose by 28%, helping to boost production capacity and market competitiveness.

Patient preference is also shifting toward cannabis-based treatments. A 2024 survey revealed that 62% of individuals dealing with anxiety or PTSD reported improvements using CBD products. With Europe's aging population—expected to reach 22% aged 65 and older by 2030—demand for natural, alternative treatment options is projected to rise steadily, further driving Europe medical cannabis market growth.

Germany is once again at the forefront by integrating medical cannabis into public health insurance. In 2024, more than 1.2 million patients benefited from this coverage, many of them seniors. Younger populations are also embracing cannabis as a therapeutic option. Platforms like Algea Care saw a 55% increase in patients under 35, primarily for conditions such as ADHD. Meanwhile, pharmaceutical companies are expanding their presence in the region—Jazz Pharmaceuticals, for instance, launched Sativex® in Spain and Poland to treat multiple sclerosis.

Despite rising demand, supply remains a concern. Although additional cultivation licenses were issued across the EU in 2024, demand continues to outpace domestic production. As a result, Europe relies heavily on imports from Canada and Israel. To address this gap, strategic partnerships are emerging. UK-based Curaleaf’s acquisition of Aurora Europe aims to strengthen its foothold in Germany, Austria, and Switzerland. Similarly, Denmark’s Stenocare is collaborating with Poland’s Herbionica to boost output by 2026.

Research is pushing the Europe medical cannabis industry forward as well. A 2024 study by the University of Leiden and Tilray explored cannabis use in managing chemotherapy-induced nausea, potentially influencing treatment guidelines across the continent. Access is also improving through digital platforms. In Italy and Greece, online clinics like Cannify and Vayamed reported a 73% increase in virtual consultations, making care more accessible.

However, pricing inconsistencies persist. Monthly costs for medical cannabis can reach €1,200 in France, compared to around €300 in the Netherlands. These high costs sometimes drive patients toward unregulated alternatives. Nevertheless, the long-term outlook for the European medical cannabis market size remains positive. Smaller producers face rising operational costs—up 18% in 2024—but many are adopting sustainable practices to offset expenses. Dutch supplier Bedrocan, for example, now operates entirely on renewable energy.

Public advocacy is also playing a vital role. In 2024, efforts by patient groups led to 11 more countries adding medical cannabis to their national healthcare services. Challenges like lingering stigma in Eastern Europe and complex border regulations still exist, but the overall trend is one of progress. As technologies advance, personalized treatments expand, and public support strengthens, the Europe medical cannabis market share is set to grow steadily. With improved regulation and broader acceptance, more patients will gain access to the care they need, securing a strong future for the European medical cannabis market.

Europe Medical Cannabis Market Segmentation: 

The report segments the market based on product type, distribution channel, and region:

Study Period:

Base Year: 2024

Historical Year: 2019-2024

Forecast Year: 2025-2033

Breakup by Species:

1. Indica

2. Sativa

3. Hybrid

Breakup by Derivative:

1. Cannabidiol (CBD)

2. Tetrahydrocannabinol (THC)

3. Others

Breakup by Application:

1. Cancer

2. Arthritis

3. Migraine

4. Epilepsy

5. Others

Breakup by End Use:

1. Pharmaceutical Industry

2. Research and Development Centers

3. Others 

Breakup by Route of Administration:

1. Oral Solutions and Capsules

2. Smoking

3. Vaporizers

4. Topicals

5. Others

Breakup by Country:

1. Germany

2. France

3. United Kingdom

4. Italy

5. Spain

6. Others

Competitive Landscape:

The market research report offers an in-depth analysis of the competitive landscape, covering market structure, key player positioning, top winning strategies, a competitive dashboard, and a company evaluation quadrant. Additionally, detailed profiles of all major companies are included.

Contact Us: 

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145